• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Pauls Matthew exercised 5,937 shares at a strike of $4.60 and sold $424,797 worth of shares (5,937 units at $71.55) (SEC Form 4)

    3/31/25 7:24:33 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $SLNO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Pauls Matthew

    (Last) (First) (Middle)
    100 MARINE PARKWAY, SUITE 400

    (Street)
    REDWOOD CITY CA 94065

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    SOLENO THERAPEUTICS INC [ SLNO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/28/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/28/2025 M 5,937 A $4.6 12,437(1) D
    Common Stock 03/28/2025 S 5,937 D $71.5508(2) 6,500(1) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee stock option (right to buy) $46.31 03/28/2025 M 5,937 (3) 08/15/2033 Common Stock 5,937 $0 9,063 D
    Explanation of Responses:
    1. Certain of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
    2. This transaction was executed in multiple trades at prices ranging from $71.54 to $71.69. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
    3. One forty-eighth (1/48th) of the shares subject to the Option shall vest on September 15, 2023 and each month thereafter on the same day of the month, subject to the Reporting Person continuing to be a Service Provider through each such date.
    /s/ Anish Bhatnagar, Attorney-in-Fact 03/31/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SLNO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLNO

    DatePrice TargetRatingAnalyst
    8/20/2025$123.00Overweight
    Wells Fargo
    6/23/2025$110.00Buy
    TD Cowen
    3/5/2025$74.00Buy
    Stifel
    12/2/2024$74.00Buy
    Stifel
    12/2/2024$72.00Outperform
    Robert W. Baird
    9/3/2024$70.00Buy
    H.C. Wainwright
    5/10/2024$72.00Outperform
    Robert W. Baird
    2/5/2024$93.00Overweight
    Piper Sandler
    More analyst ratings

    $SLNO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results

    REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 and Recent Corporate Highlights Announced launch of VYKAT XR and commencement of patient treatments on April 14, 2025.From approval on March 26, 2025 through June 30, 2025, Soleno reports: 646 patient start forms received295 unique prescribers of VYKAT XROver 100 million lives covered Announced submission and validation of Market

    8/6/25 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET

    REDWOOD CITY, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its second quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, August 6, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, August 6, 2025Time:4:30 PM Eastern TimeUnited States:1-800-717-1738International:1-646-307-1865Con

    7/28/25 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

    REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. All of the shares are being sold by Soleno. In addition, Soleno has granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price. The gross proceeds from the offering are expected to be approximately $200 million before deducting underwriting disc

    7/10/25 9:07:23 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    SEC Filings

    View All

    Soleno Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

    8/18/25 6:54:43 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.

    SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    8/14/25 4:35:25 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.

    SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    8/14/25 1:07:20 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Perceptive Advisors Llc bought $15,113,916 worth of shares (866,789 units at $17.44) (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    9/28/23 3:45:22 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Financials

    Live finance-specific insights

    View All

    Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results

    REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 and Recent Corporate Highlights Announced launch of VYKAT XR and commencement of patient treatments on April 14, 2025.From approval on March 26, 2025 through June 30, 2025, Soleno reports: 646 patient start forms received295 unique prescribers of VYKAT XROver 100 million lives covered Announced submission and validation of Market

    8/6/25 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET

    REDWOOD CITY, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its second quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, August 6, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, August 6, 2025Time:4:30 PM Eastern TimeUnited States:1-800-717-1738International:1-646-307-1865Con

    7/28/25 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

    REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Recent Corporate Highlights Announced U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). Announced launch and commencement of pati

    5/7/25 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Leadership Updates

    Live Leadership Updates

    View All

    Soleno Therapeutics Set to Join Russell 3000® Index

    REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "Inclusion in the Russell indexes is a significant milestone and reflects the meaningful progress Soleno has made in advancing our lead candidate DCCR (diazoxide choline) extended-release ta

    6/4/24 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Strengthens Leadership Team with Key Appointments

    REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources. The Company also announced the appointment of key advisors with Shamim Ruff, M.S. joining as Chair of the Development Advisory Board and James (Jim) Geraghty, J.D., M.S. as a Board Advisor. "As we move into the next phase of Soleno's growth, we are delighted to welcome seasone

    1/24/24 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors

    REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023. Mr. Pauls is an accomplished industry veteran with extensive executive leadership, strategic and commercial experience. "Matt is a highly accomplished biopharmaceutical executive, and we are pleased to welcome him to the Board," said Ernest Mario, Ph.D., Chairman of the Board of Directors of Soleno. "His impressive track record, including in rare diseases, will b

    8/16/23 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/19/24 9:44:27 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/14/24 4:30:58 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Soleno Therapeutics Inc.

    SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/14/24 12:51:18 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Hirano Patricia C sold $316,971 worth of shares (3,830 units at $82.76), decreasing direct ownership by 22% to 13,206 units (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    7/3/25 4:41:13 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Officer Hirano Patricia C exercised 266 shares at a strike of $44.25 and sold $22,410 worth of shares (266 units at $84.25) (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    6/26/25 6:04:57 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Volck Birgitte was granted 3,991 shares, increasing direct ownership by 29% to 17,536 units (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    6/9/25 7:27:59 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Soleno Therapeutics with a new price target

    Wells Fargo initiated coverage of Soleno Therapeutics with a rating of Overweight and set a new price target of $123.00

    8/20/25 9:01:56 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    TD Cowen initiated coverage on Soleno Therapeutics with a new price target

    TD Cowen initiated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $110.00

    6/23/25 8:09:37 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stifel resumed coverage on Soleno Therapeutics with a new price target

    Stifel resumed coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $74.00

    3/5/25 7:44:16 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care